This page is intended for UK healthcare professionals and other relevant decision makers only. If you are a member of the public, please click here.
This portal is funded and owned by Novartis Pharmaceuticals UK Ltd and includes content approved by Novartis.
Adverse events reporting information can be found in the footer of this page.
PRRT: revisiting the Lutathera® ([177Lu]Lu-oxodotreotide) SmPC
Dr Gopinath Gnanasegaran
Dr Gopinath Gnanasegaran, Consultant in Nuclear Medicine at the...
Dr John Buscombe
Dr John Buscombe, Locum Consultant Physician in Nuclear Medicine at Barts...
The role of the NET nurse in the PRRT referral pathway
Mike Tadman
Mike Tadman, Senior Specialist Neuroendocrine Cancer Nurse at Oxford...
The role of MDT in NET management: when to consider PRRT in GEP-NETs
Dr Christos Toumpanakis
Dr Christos Toumpanakis, Consultant in...